1. Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: Result in a cohort of 203 resection specimens 
Aneil A. Mujoomdar, MD, Tamara R. Tilleman, MD, PhD, William G. Richards, PhD, Raphael Bueno, MD, David J. Sugarbaker, MD 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 140, Issue 2, Pages (August 2010)
DOI: /j.jtcvs
Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

2. Figure 1
Drug resistance assay results among malignant pleural mesothelioma tumors.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

3. Figure 2
Venn diagram: EDR and IDR for mesothlioma specimens. EDR, Extreme drug resistance; IDR, intermediate drug resistance.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

4. Figure 3
Drug resistance in tumors with epithelial histology. Note: Y-axis is percentage.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

5. Figure 4
Drug resistance in tumors with nonepithelial histology. Note: Y-axis is percentage.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions